Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5548,DB00394,Beclomethasone
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5549,DB00394,Beclomethasone
,16029067,mass median,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5550,DB00394,Beclomethasone
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,1.1,5551,DB00394,Beclomethasone
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,4.0,5552,DB00394,Beclomethasone
,16029067,aerodynamic diameter,"Compared to the reference beclometasone dipropionate formulation, the mass median aerodynamic diameter of the Qvar formulations are substantially smaller (1.1 vs 4.0 microm), whereas that of Modulite averages 2.6 microm.",Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029067/),μm,2.6,5553,DB00394,Beclomethasone
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],5280,24541,DB00394,Beclomethasone
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],8120,24542,DB00394,Beclomethasone
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],353,24543,DB00394,Beclomethasone
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],190,24544,DB00394,Beclomethasone
,17883883,oral bioavailability,Its oral bioavailability is poor (6.7%).,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),%,6.7,29050,DB00394,Beclomethasone
,17883883,Plasma half-life,Plasma half-life is estimated to be 3.9 to 4.6 hours.,A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,3.9 to 4.6,29051,DB00394,Beclomethasone
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),l,96,29052,DB00394,Beclomethasone
,17883883,terminal half-life,"FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively).",A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883883/),h,1.6,29053,DB00394,Beclomethasone
,10632080,maximum concentrations (Cmax),"Following a 400 microg beclomethasone dipropionate dose, the HFA formulation gave mean maximum concentrations (Cmax) and area under the curve (AUC) values of beclomethasone esters of 1153 pg mL(-1) and 4328 pg h mL(-1), respectively, and beclomethasone Cmax and AUC values of 69 pg mL(-1) and 682 pg h mL(-1), respectively.",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[pg] / [ml],1153,45983,DB00394,Beclomethasone
,10632080,area under the curve (AUC),"Following a 400 microg beclomethasone dipropionate dose, the HFA formulation gave mean maximum concentrations (Cmax) and area under the curve (AUC) values of beclomethasone esters of 1153 pg mL(-1) and 4328 pg h mL(-1), respectively, and beclomethasone Cmax and AUC values of 69 pg mL(-1) and 682 pg h mL(-1), respectively.",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[h·pg] / [ml],4328,45984,DB00394,Beclomethasone
,10632080,Cmax,"Following a 400 microg beclomethasone dipropionate dose, the HFA formulation gave mean maximum concentrations (Cmax) and area under the curve (AUC) values of beclomethasone esters of 1153 pg mL(-1) and 4328 pg h mL(-1), respectively, and beclomethasone Cmax and AUC values of 69 pg mL(-1) and 682 pg h mL(-1), respectively.",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[pg] / [ml],69,45985,DB00394,Beclomethasone
,10632080,AUC,"Following a 400 microg beclomethasone dipropionate dose, the HFA formulation gave mean maximum concentrations (Cmax) and area under the curve (AUC) values of beclomethasone esters of 1153 pg mL(-1) and 4328 pg h mL(-1), respectively, and beclomethasone Cmax and AUC values of 69 pg mL(-1) and 682 pg h mL(-1), respectively.",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[h·pg] / [ml],682,45986,DB00394,Beclomethasone
,10632080,Cmax,"These values were approximately 2-3-fold those seen with the CFC formulation (beclomethasone esters Cmax and AUC of 380 pg mL(-1) and 1764 pg h mL(-1), respectively; beclomethasone Cmax and AUC of 41 pg ml(-1) and 366 pg h mL(-1), respectively).",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[pg] / [ml],380,45987,DB00394,Beclomethasone
,10632080,AUC,"These values were approximately 2-3-fold those seen with the CFC formulation (beclomethasone esters Cmax and AUC of 380 pg mL(-1) and 1764 pg h mL(-1), respectively; beclomethasone Cmax and AUC of 41 pg ml(-1) and 366 pg h mL(-1), respectively).",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[h·pg] / [ml],1764,45988,DB00394,Beclomethasone
,10632080,Cmax,"These values were approximately 2-3-fold those seen with the CFC formulation (beclomethasone esters Cmax and AUC of 380 pg mL(-1) and 1764 pg h mL(-1), respectively; beclomethasone Cmax and AUC of 41 pg ml(-1) and 366 pg h mL(-1), respectively).",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[pg] / [ml],41,45989,DB00394,Beclomethasone
,10632080,AUC,"These values were approximately 2-3-fold those seen with the CFC formulation (beclomethasone esters Cmax and AUC of 380 pg mL(-1) and 1764 pg h mL(-1), respectively; beclomethasone Cmax and AUC of 41 pg ml(-1) and 366 pg h mL(-1), respectively).",Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632080/),[h·pg] / [ml],366,45990,DB00394,Beclomethasone
,17439539,mass median aerodynamic diameters (MMADs),"In a randomized single-blind crossover trial, 10 mild asthmatic patients inhaled monodisperse BDP aerosols with mass median aerodynamic diameters (MMADs) of 1.5, 2.5 and 4.5 microm.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),μm,1.5,47224,DB00394,Beclomethasone
,17439539,mass median aerodynamic diameters (MMADs),"In a randomized single-blind crossover trial, 10 mild asthmatic patients inhaled monodisperse BDP aerosols with mass median aerodynamic diameters (MMADs) of 1.5, 2.5 and 4.5 microm.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),μm,2.5,47225,DB00394,Beclomethasone
,17439539,mass median aerodynamic diameters (MMADs),"In a randomized single-blind crossover trial, 10 mild asthmatic patients inhaled monodisperse BDP aerosols with mass median aerodynamic diameters (MMADs) of 1.5, 2.5 and 4.5 microm.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),μm,4.5,47226,DB00394,Beclomethasone
,17439539,maximum concentrations (C(max)),"Aerosols with MMADs of 1.5 microm, 2.5 microm, and 4.5 microm gave mean maximum concentrations (C(max)) of 17-BMP of 475 pg ml(-1), 1300 pg ml(-1), and 1161 pg ml(-1), respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[pg] / [ml],475,47227,DB00394,Beclomethasone
,17439539,maximum concentrations (C(max)),"Aerosols with MMADs of 1.5 microm, 2.5 microm, and 4.5 microm gave mean maximum concentrations (C(max)) of 17-BMP of 475 pg ml(-1), 1300 pg ml(-1), and 1161 pg ml(-1), respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[pg] / [ml],1300,47228,DB00394,Beclomethasone
,17439539,maximum concentrations (C(max)),"Aerosols with MMADs of 1.5 microm, 2.5 microm, and 4.5 microm gave mean maximum concentrations (C(max)) of 17-BMP of 475 pg ml(-1), 1300 pg ml(-1), and 1161 pg ml(-1), respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[pg] / [ml],1161,47229,DB00394,Beclomethasone
,17439539,area under the curve (AUC),"The area under the curve (AUC) values of 17-BMP for MMADs of 1.5 microm, 2.5 microm, and 4.5 microm were 825 pg ml(-1) h, 2629 pg ml(-1) h, and 2276 pg ml(-1) h, respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[h·pg] / [ml],825,47230,DB00394,Beclomethasone
,17439539,area under the curve (AUC),"The area under the curve (AUC) values of 17-BMP for MMADs of 1.5 microm, 2.5 microm, and 4.5 microm were 825 pg ml(-1) h, 2629 pg ml(-1) h, and 2276 pg ml(-1) h, respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[h·pg] / [ml],2629,47231,DB00394,Beclomethasone
,17439539,area under the curve (AUC),"The area under the curve (AUC) values of 17-BMP for MMADs of 1.5 microm, 2.5 microm, and 4.5 microm were 825 pg ml(-1) h, 2629 pg ml(-1) h, and 2276 pg ml(-1) h, respectively.",Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),[h·pg] / [ml],2276,47232,DB00394,Beclomethasone
,17439539,terminal half-time,The mean terminal half-time of 17-BMP for all three aerosol sizes was around 1.5 h.,Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17439539/),h,1.5,47233,DB00394,Beclomethasone
,32968868,EE%,The prepared cubosomes were of nano-sizes (100 nm - 278 nm); EE% was around 94%.,Preparation and Evaluation of Cubosomes/Cubosomal Gels for Ocular Delivery of Beclomethasone Dipropionate for Management of Uveitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32968868/),%,94,54700,DB00394,Beclomethasone
,12567387,systemic bioavailabilities,"The mean systemic bioavailabilities in percent of dose leaving the canister valve (ex-valve) were 70% (100 HFA), 74% (200 HFA), 60% (200 HFA + charcoal), and 27% (400 microg CFC).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),%,70,67315,DB00394,Beclomethasone
,12567387,systemic bioavailabilities,"The mean systemic bioavailabilities in percent of dose leaving the canister valve (ex-valve) were 70% (100 HFA), 74% (200 HFA), 60% (200 HFA + charcoal), and 27% (400 microg CFC).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),%,74,67316,DB00394,Beclomethasone
,12567387,systemic bioavailabilities,"The mean systemic bioavailabilities in percent of dose leaving the canister valve (ex-valve) were 70% (100 HFA), 74% (200 HFA), 60% (200 HFA + charcoal), and 27% (400 microg CFC).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),%,60,67317,DB00394,Beclomethasone
,12567387,systemic bioavailabilities,"The mean systemic bioavailabilities in percent of dose leaving the canister valve (ex-valve) were 70% (100 HFA), 74% (200 HFA), 60% (200 HFA + charcoal), and 27% (400 microg CFC).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),%,27,67318,DB00394,Beclomethasone
,12567387,bioavailability,The estimated bioavailability of BDP from the GI tract was 68%.,Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),%,68,67319,DB00394,Beclomethasone
,12567387,steady-state volume of distribution,"Mean steady-state volume of distribution of 17-BMP was 84 L, and the mean terminal half-life (T((1/2))) after the four inhalations was 2.7 hr (range, 2.2-3.7 hr).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),l,84,67320,DB00394,Beclomethasone
,12567387,terminal half-life (T((1/2))),"Mean steady-state volume of distribution of 17-BMP was 84 L, and the mean terminal half-life (T((1/2))) after the four inhalations was 2.7 hr (range, 2.2-3.7 hr).",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),h,2.7,67321,DB00394,Beclomethasone
,12567387,T((1/2)),"Mean T((1/2)) and clearance after i.v. administration were 1.7 hr and 0.9 L/min, respectively.",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),h,1.7,67322,DB00394,Beclomethasone
,12567387,clearance,"Mean T((1/2)) and clearance after i.v. administration were 1.7 hr and 0.9 L/min, respectively.",Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12567387/),[l] / [min],0.9,67323,DB00394,Beclomethasone
,23523547,aerodynamic,"By modifying the formulation parameters, including actuator orifice, HFA and metering volumes, it was possible to produce two formulations (glycerol-free and glycerol-containing) which had identical mass median aerodynamic diameters (2.4μm±0.1 and 2.5μm±0.2), fine particle dose (⩽5μm; 66μg±6 and 68μg±2) and fine particle fractions (28%±2% and 30%±1%), respectively.",Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523547/),μm,2.4,91196,DB00394,Beclomethasone
,23523547,aerodynamic,"By modifying the formulation parameters, including actuator orifice, HFA and metering volumes, it was possible to produce two formulations (glycerol-free and glycerol-containing) which had identical mass median aerodynamic diameters (2.4μm±0.1 and 2.5μm±0.2), fine particle dose (⩽5μm; 66μg±6 and 68μg±2) and fine particle fractions (28%±2% and 30%±1%), respectively.",Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523547/),μm,2.5,91197,DB00394,Beclomethasone
,10370197,total drug output,"However, in the total drug output during the inhalation there was a relatively large difference between DLPC and DPPC of 11.4 and 3.1 microg, respectively.",Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10370197/),μ,11.4,95663,DB00394,Beclomethasone
,10370197,total drug output,"However, in the total drug output during the inhalation there was a relatively large difference between DLPC and DPPC of 11.4 and 3.1 microg, respectively.",Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10370197/),μ,3.1,95664,DB00394,Beclomethasone
,28937845,elimination half-life,Mean elimination half-life was ∼4 hours.,Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28937845/),h,∼4,102465,DB00394,Beclomethasone
,22621776,AUC(last),"Mean AUC(last) values of 17-BMP for intranasal 80 μg, intranasal 320 μg, and orally inhaled 320 μg were 295.8, 1139.7, and 4140.3 pg·hr/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[h·pg] / [ml],295.8,119570,DB00394,Beclomethasone
,22621776,AUC(last),"Mean AUC(last) values of 17-BMP for intranasal 80 μg, intranasal 320 μg, and orally inhaled 320 μg were 295.8, 1139.7, and 4140.3 pg·hr/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[h·pg] / [ml],1139.7,119571,DB00394,Beclomethasone
,22621776,AUC(last),"Mean AUC(last) values of 17-BMP for intranasal 80 μg, intranasal 320 μg, and orally inhaled 320 μg were 295.8, 1139.7, and 4140.3 pg·hr/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[h·pg] / [ml],4140.3,119572,DB00394,Beclomethasone
,22621776,C(max),"Mean C(max) values were 92.1, 262.7, and 1343.7 pg/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[pg] / [ml],92.1,119573,DB00394,Beclomethasone
,22621776,C(max),"Mean C(max) values were 92.1, 262.7, and 1343.7 pg/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[pg] / [ml],262.7,119574,DB00394,Beclomethasone
,22621776,C(max),"Mean C(max) values were 92.1, 262.7, and 1343.7 pg/mL, respectively.","Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22621776/),[pg] / [ml],1343.7,119575,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],2822.3,128799,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],5454.9,128800,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],771.6,128801,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],1138.9,128802,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],38.4,128803,DB00394,Beclomethasone
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],54.7,128804,DB00394,Beclomethasone
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.11,138663,DB00394,Beclomethasone
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],-0.15,138664,DB00394,Beclomethasone
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.4,138665,DB00394,Beclomethasone
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.7,138666,DB00394,Beclomethasone
,18321744,elimination half-life,"The active metabolite of BDP is beclomethasone-17-monopropriate (B17MP), which reached Cmax at 0.25 h, with an elimination half-life of 3.7 h.",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),h,3.7,138667,DB00394,Beclomethasone
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB00394,Beclomethasone
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB00394,Beclomethasone
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB00394,Beclomethasone
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB00394,Beclomethasone
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB00394,Beclomethasone
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB00394,Beclomethasone
,16597076,forced expiratory volume in 1 second,"Fifteen asthmatic patients (mean +/- SEM forced expiratory volume in 1 second [FEV1], 2.62 +/- 0.21 L; provocative concentration of methacholine causing a 20% decrease in FEV1 [PC20], 1.06 +/- 0.58) were randomized to completion in a placebo-controlled, double-blind, crossover manner to receive Beclate or Qvar at doses of 100 or 400 microg/d for 2 weeks, with a 1-week washout period before each randomized treatment.",A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597076/),l,2.62,149135,DB00394,Beclomethasone
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB00394,Beclomethasone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],"1,587",162622,DB00394,Beclomethasone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],455,162623,DB00394,Beclomethasone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],758,162624,DB00394,Beclomethasone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,1.3,162625,DB00394,Beclomethasone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,3,162626,DB00394,Beclomethasone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,2.5,162627,DB00394,Beclomethasone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,4.6,162628,DB00394,Beclomethasone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,7.4,162629,DB00394,Beclomethasone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,6.3,162630,DB00394,Beclomethasone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,5.4,162631,DB00394,Beclomethasone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,11.1,162632,DB00394,Beclomethasone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,10.0,162633,DB00394,Beclomethasone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [h·ml],"6,883",162634,DB00394,Beclomethasone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [h·ml],"8,201",162635,DB00394,Beclomethasone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],"4,870",162636,DB00394,Beclomethasone
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,34.08,176657,DB00394,Beclomethasone
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,30.86,176658,DB00394,Beclomethasone
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,33.10,176659,DB00394,Beclomethasone
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,53.48,176660,DB00394,Beclomethasone
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,57.64,176661,DB00394,Beclomethasone
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,54.98,176662,DB00394,Beclomethasone
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.42,176663,DB00394,Beclomethasone
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.96,176664,DB00394,Beclomethasone
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.94,176665,DB00394,Beclomethasone
,9673781,BOH availability,The BOH availability of orally administered BDP was approximately 40% relative to inhaled HFA BDP.,Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134A metered dose inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673781/),%,40,191029,DB00394,Beclomethasone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],334,204818,DB00394,Beclomethasone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],357,204819,DB00394,Beclomethasone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],366,204820,DB00394,Beclomethasone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],297,204821,DB00394,Beclomethasone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],336,204822,DB00394,Beclomethasone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],328,204823,DB00394,Beclomethasone
,1676668,plasma elimination half-life,"BUD was rapidly absorbed from the lung, and its plasma elimination half-life was about 3 hr.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),h,3,215887,DB00394,Beclomethasone
,1676668,oral bioavailability,"Assuming that BDP was transformed entirely into BMP, the oral bioavailability of BMP at 1.5 mg/kg was around 72%, while that of BUD was 15%.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),%,72,215888,DB00394,Beclomethasone
,1676668,oral bioavailability,"Assuming that BDP was transformed entirely into BMP, the oral bioavailability of BMP at 1.5 mg/kg was around 72%, while that of BUD was 15%.","Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676668/),%,15,215889,DB00394,Beclomethasone
,17075274,area under the concentration-time curve from time zero to the last quantifiable time (AUC(0-t)),"The area under the concentration-time curve from time zero to the last quantifiable time (AUC(0-t)) was 1659 +/- 850 pg x h/mL (arithmetic mean +/- standard deviation (SD)), the maximum concentration observed (C(max)) was 825 +/- 453 pg/mL and the apparent elimination half-life (t(1/2)) was 2.1 +/- 0.7 hours.",Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075274/),[h·pg] / [ml],1659,224304,DB00394,Beclomethasone
,17075274,maximum concentration observed (C(max)),"The area under the concentration-time curve from time zero to the last quantifiable time (AUC(0-t)) was 1659 +/- 850 pg x h/mL (arithmetic mean +/- standard deviation (SD)), the maximum concentration observed (C(max)) was 825 +/- 453 pg/mL and the apparent elimination half-life (t(1/2)) was 2.1 +/- 0.7 hours.",Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075274/),[pg] / [ml],825,224305,DB00394,Beclomethasone
,17075274,apparent elimination half-life (t(1/2)),"The area under the concentration-time curve from time zero to the last quantifiable time (AUC(0-t)) was 1659 +/- 850 pg x h/mL (arithmetic mean +/- standard deviation (SD)), the maximum concentration observed (C(max)) was 825 +/- 453 pg/mL and the apparent elimination half-life (t(1/2)) was 2.1 +/- 0.7 hours.",Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075274/),h,2.1,224306,DB00394,Beclomethasone
,17075274,time to reach Cmax Tmax,The time to reach Cmax Tmax was 0.5 hours in all patients.,Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075274/),h,0.5,224307,DB00394,Beclomethasone
,17075274,Tmax,The median of Tmax was 0.5 hours in American patients as well as Japanese patients.,Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075274/),h,0.5,224308,DB00394,Beclomethasone
,18757252,flow rate,"Both compounds were extracted from human plasma with ether-cyclohexane (4:1, v/v) and were separated by HPLC on a Hanbon Lichrospher C(18) column with a mobile phase of methanol-water (85:15, v/v) at a flow rate of 0.7ml/min.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),[ml] / [min],0.7,230243,DB00394,Beclomethasone
,18757252,plasma extraction recovery,"The mean plasma extraction recovery for BOH and B17P were in the ranges of 82.7-85.9% and 83.6-85.3%, respectively.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),%,82.7-85.9,230244,DB00394,Beclomethasone
,18757252,plasma extraction recovery,"The mean plasma extraction recovery for BOH and B17P were in the ranges of 82.7-85.9% and 83.6-85.3%, respectively.",Determination of betamethasone and betamethasone 17-monopropionate in human plasma by liquid chromatography-positive/negative electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757252/),%,83.6-85.3,230245,DB00394,Beclomethasone
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,22,230887,DB00394,Beclomethasone
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,7.9,230888,DB00394,Beclomethasone
,2332564,Time to relapse,"Time to relapse was longer with inhaled than with oral BUD (medians, 22 versus 7.9 days; p = 0.003) or placebo (medians, 22 versus 9 days; p = 0.004).",A study of the mechanism of the antiasthmatic action of inhaled budesonide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2332564/),d,9,230889,DB00394,Beclomethasone
,12581506,L/T ratios,"From five deposition and pharmacokinetic studies, L/T ratios for CFC-BDP and HFA-BDP were calculated as 0.21 and 0.92, respectively.",Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12581506/),,0.21,231869,DB00394,Beclomethasone
,12581506,L/T ratios,"From five deposition and pharmacokinetic studies, L/T ratios for CFC-BDP and HFA-BDP were calculated as 0.21 and 0.92, respectively.",Local versus total systemic bioavailability of beclomethasone dipropionate CFC and HFA metered dose inhaler formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12581506/),,0.92,231870,DB00394,Beclomethasone
,11421996,CL,"Intravenous administration of BDP (mean CL 150 l h-1, Vss 20 l, t(1/2) 0.5 h) was associated with rapid conversion to B-17-MP which was eliminated more slowly (t1/2 2.7 h).","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),[l] / [h],150,258869,DB00394,Beclomethasone
,11421996,Vss,"Intravenous administration of BDP (mean CL 150 l h-1, Vss 20 l, t(1/2) 0.5 h) was associated with rapid conversion to B-17-MP which was eliminated more slowly (t1/2 2.7 h).","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),l,20,258870,DB00394,Beclomethasone
,11421996,t(1/2),"Intravenous administration of BDP (mean CL 150 l h-1, Vss 20 l, t(1/2) 0.5 h) was associated with rapid conversion to B-17-MP which was eliminated more slowly (t1/2 2.7 h).","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),h,0.5,258871,DB00394,Beclomethasone
,11421996,t1/2,"Intravenous administration of BDP (mean CL 150 l h-1, Vss 20 l, t(1/2) 0.5 h) was associated with rapid conversion to B-17-MP which was eliminated more slowly (t1/2 2.7 h).","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),h,2.7,258872,DB00394,Beclomethasone
,11421996,CL,"In estimating the parameters for B-17-MP (mean CL 120 l h-1, Vss 424 l) complete conversion of BDP to B-17-MP was assumed.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),[l] / [h],120,258873,DB00394,Beclomethasone
,11421996,Vss,"In estimating the parameters for B-17-MP (mean CL 120 l h-1, Vss 424 l) complete conversion of BDP to B-17-MP was assumed.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),l,424,258874,DB00394,Beclomethasone
,11421996,absolute bioavailability (%F,"The mean absolute bioavailability (%F, 90% CI; nominal doses) of inhaled BDP was 2% (1-4%) and not reduced by coadministration of charcoal.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),%,2,258875,DB00394,Beclomethasone
,11421996,percentage F,"The mean percentage F of the active metabolite B-17-MP was 41% (31-54%), 44% (34-58%) and 62% (47-82%) for oral, intranasal and inhaled dosing without charcoal, respectively.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),,41,258876,DB00394,Beclomethasone
,11421996,percentage F,"The mean percentage F of the active metabolite B-17-MP was 41% (31-54%), 44% (34-58%) and 62% (47-82%) for oral, intranasal and inhaled dosing without charcoal, respectively.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),%,44,258877,DB00394,Beclomethasone
,11421996,percentage F,"The mean percentage F of the active metabolite B-17-MP was 41% (31-54%), 44% (34-58%) and 62% (47-82%) for oral, intranasal and inhaled dosing without charcoal, respectively.","Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),,62,258878,DB00394,Beclomethasone
,11421996,total inhaled bioavailability,The total inhaled bioavailability of B-17-MP (lung + oral) was also high (62%) and approximately 36% of this was due to pulmonary absorption.,"Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),%,62,258879,DB00394,Beclomethasone
,11421996,total inhaled bioavailability,The total inhaled bioavailability of B-17-MP (lung + oral) was also high (62%) and approximately 36% of this was due to pulmonary absorption.,"Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421996/),%,36,258880,DB00394,Beclomethasone
,12107606,t(1/2),The t(1/2) of 17-BMP was found to be approximately 2.8 h.,Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107606/),h,2.8,264380,DB00394,Beclomethasone
,6958498,plasma half-life,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),h,2.8,266547,DB00394,Beclomethasone
,6958498,distribution volume,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),1,301.3,266548,DB00394,Beclomethasone
,6958498,plasma clearance,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),[1] / [h],83.7,266549,DB00394,Beclomethasone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,10.7,266550,DB00394,Beclomethasone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,72.8,266551,DB00394,Beclomethasone
